Table of Contents

• 1.   Market Introduction
  •   1. Objectives of the Study
      2. Market Definition
      3. Market Scope
       3.1 . Years Considered for the Study
       3.2 . Market Covered
      4. Currency
      5. Limitations
      6. Stakeholders
    
• 2.   Research Methodology
  •   1. Research Data
       1.1 . Secondary Data
        1.1.1 . Key Data from Secondary Sources
       1.2 . Primary Data
        1.2.1. Key Data from Primary Sources
      2. Market Size Estimation
      3. Market Breakdown and Data Triangulation
      4. Assumptions for the Study
    
• 3.   Executive Summary
  •   1. Market Outlook
      2. Segment Outlook
      3. Competitive Insights
    
• 4.   Europe Early Toxicity Testing Market Variables, Trends and Scope

  •   1. Market Lineage Outlook
      2. Penetration and Growth Prospect Mapping
      3. Industry Value Chain Analysis
      4. Cost Analysis Breakdown
      5. Technology Overview
      6. Regulatory Framework
       6.1. Reimbursement Framework
       6.2. Standards and Compliances

• 5.   Market Overview
  •   1. Market Dynamics
       1.1. Market Driver Analysis
        1.1.1. Increasing focus of Europe Early Toxicity Testing Companies on Brand Protection
        1.1.2. Untapped Opportunities in Emerging Regions
       1.2. Market Restraint Analysis
        1.2.1. High Cost Associated with Implementation of Predictive Analysis
       1.3. Industry Challenges
        1.3.1. Presence of Ambiguous Regulatory Framework
    
• 6.   Europe Early Toxicity Testing Market Analysis Tools
  •   1. Industry Analysis - Porter’s
       1.1. Supplier Power
       1.2. Buyer Power
       1.3. Substitution Threat
       1.4. Threat from New Entrants
       1.5. Competitive Rivalry
      2. Pestel Analysis
       2.1. Political Landscape
       2.2. Environmental Landscape
       2.3. Social Landscape
       2.4. Technology Landscape
       2.5. Legal Landscape
      3. Major Deals And Strategic Alliances Analysis
       3.1. Joint Ventures
       3.2. Mergers and Acquisitions
       3.3. Licensing and Partnership
       3.4. Technology Collaborations
       3.5. Strategic Divestments
      4. Market Entry Strategies
      5. Case Studies
    
• 7.   Europe Early Toxicity Testing Market, By Technique Historical Analysis and Forecast 2023-2031 (USD Million)

  •   1. In Vivo
      2. In Vitro
       2.1. By Assays
        2.1.1. Enzyme Toxicity Assays
        2.1.2. Bacterial Toxicity Assays
        2.1.3. Cell-based ELISA and Western Blots
        2.1.4. Tissues Culture Assays
        2.1.5. Receptor Binding Assays
        2.1.6. Other Assays
       2.2. By Toxicity End-Points and Tests
        2.2.1. Dermal Toxicity
        2.2.2. Systemic Toxicity
        2.2.3. Carcinogenicity
        2.2.4. Ocular Toxicity
        2.2.5. Skin Sensitization and Irritation
        2.2.6. Genotoxicity
        2.2.7. Neurotoxicity
        2.2.8. Organ Toxicity
        2.2.9. Other Toxicity Endpoints and Tests
      3. In Silico

• 8.   Europe Early Toxicity Testing Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)

  •   1. Drug discovery
      2. Chemical testing
      3. Others

• 9.   Europe Early Toxicity Testing Market, By End-User Historical Analysis and Forecast 2023-2031 (USD Million)

  •   1. Pharmaceuticals Industry
      2. Food Industry
      3. Chemicals Industry
      4. Cosmetics Industry
      5. Other Industries

• 10.  Europe Early Toxicity Testing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

  •   1. Introduction
      2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
       2.1. Germany
       2.2. U.K
       2.3. France
       2.4. Italy
       2.5. Spain
       2.6. Russia
       2.7. Poland
       2.8. Rest of Europe
      3. Market Size (USD Million) Forecast for Europe 2023-2031

• 11.   Market Share Analysis and Competitive Landscape
  •   1. Europe Landscape - Key Players, Revenue and Presence
      2. Europe Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
      3. Europe Emerging Companies
      4. Europe - Market Share Analysis and Key Regional Players
      5. Europe Key Player - Growth Matrix
    
• 12.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Techniques Offered and Financial Layouts)

  •   1. Agilent Technologies, Inc.
       1.1. Company Overview
       1.2. Product Portfolio
       1.3. SWOT Analysis
       1.4. Financial Overview
       1.5. Strategic Overview
      2. General Electric Company (GE Healthcare)
       2.1. Company Overview
       2.2. Product Portfolio
       2.3. SWOT Analysis
       2.4. Financial Overview
       2.5. Strategic Overview
      3. Danaher Corporation (Beckman Coulter, Inc.)
       3.1. Company Overview
       3.2. Product Portfolio
       3.3. SWOT Analysis
       3.4. Financial Overview
       3.5. Strategic Overview
      4. Evotec AG (Cyprotex)
       4.1. Company Overview
       4.2. Product Portfolio
       4.3. SWOT Analysis
       4.4. Financial Overview
       4.5. Strategic Overview
      5. Bioanalytical Systems, Inc.
       5.1. Company Overview
       5.2. Product Portfolio
       5.3. SWOT Analysis
       5.4. Financial Overview
       5.5. Strategic Overview
      6. Bruker Corporation
       6.1. Company Overview
       6.2. Product Portfolio
       6.3. SWOT Analysis
       6.4. Financial Overview
       6.5. Strategic Overview
      7. Thermo Fisher Scientific, Inc.
       7.1. Company Overview
       7.2. Product Portfolio
       7.3. SWOT Analysis
       7.4. Financial Overview
       7.5. Strategic Overview
      8. PerkinElmer Inc.
       8.1. Company Overview
       8.2. Product Portfolio
       8.3. SWOT Analysis
       8.4. Financial Overview
       8.5. Strategic Overview
      9. Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.)
       9.1. Company Overview
       9.2. Product Portfolio
       9.3. SWOT Analysis
       9.4. Financial Overview
       9.5. Strategic Overview
      10.The Jackson Laboratory
       10.1. Company Overview
       10.2. Product Portfolio
       10.3. SWOT Analysis
       10.4. Financial Overview
       10.5. Strategic Overview

• 13.   Pre and Post COVID-19 Impact
  •   1. Positive influence on the healthcare industry
      2. The financial disruption of the manufacturing sector
      3. Impact of COVID-19 on emerging companies
      4. Significant mandates in the healthcare regulations initiated by administrations
      5. The overall economic slowdown of the developing and developed nations
    
• 14.   FutureWise SME Key Takeaway Points for Client